CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Previously, the drugs were able to be prescribed through an email chat, from questionnaires or by people sending in photos of ...

It’s a synthetic version of the hormone GLP-1, which helps regulate our metabolism ... Some of these newer iterations, the dual agonists, have such significant weight loss that not everybody ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

The weekly injections and gastrointestinal side effects ... a subcutaneously injected, long-acting GLP-1 agonist drug. A Phase 1/2 test is underway in the U.S., enrolling participants who are ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

More and more people are taking weight loss injectables like Wegovy — but not everyone prescribed these drugs should have ...

La Boussole's program includes advanced options such as GLP-1 receptor agonist injections, such as semaglutide and tirzepatide, which help regulate blood sugar and appetite, making weight loss ...